|View printer-friendly version|
The deconsolidation occurred due to the exercise of 625,000 warrants by certain
“We continue to simplify
The impact, including the actual gain, of this deconsolidation will be recognized in BioTime’s quarterly report on Form 10-Q to be filed with the
In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
To receive ongoing